"Biotech-to-DeAI Metamorphosis: AIxCrypto Emerges as Web3 Era Gateway"

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has announced a sweeping corporate transformation, rebranding as AIxCrypto Holdings, Inc. (NASDAQ: AIXC) ahead of a formal ticker activation ceremony at Nasdaq's New York headquarters on November 20. The move, approved by shareholders in a special meeting, marks the company's pivot from biotechnology to a decentralized artificial intelligence (DeAI) and Web3 platform, with Faraday Future Intelligent Electric Inc. (FFAI) securing a controlling stake.

The rebranding follows a majority vote approving proposals that cement Faraday Future's dominance in the governance structure. Shareholders authorized the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares, pushing Faraday's ownership to approximately 55% directly and 63% including affiliated stakeholders. The company will also reconstitute its board, with Faraday Future nominating a majority of directors to oversee the strategic shift.

AIxCrypto's new business model positions it as a "leading gateway" to the AI × Web3 era, according to the firm's announcement.

The transition includes a cross-ecosystem integration with Faraday Future, which recently secured access to Tesla's Supercharger network for its 2026 electric vehicles. This alignment suggests a strategic partnership aimed at accelerating innovation in AI-driven blockchain infrastructure and decentralized technologies.

Jerry Wang, co-CEO of the rebranded entity, emphasized the transformation as "more than a renaming" but a "complete evolution" of the company's identity and technological capabilities according to the firm's announcement. The firm plans to unveil a three-year development roadmap during the November 20 ceremony, outlining its vision for AI × Web3 infrastructure, intelligent trading systems, and decentralized asset platforms.

The rebranding aligns with broader trends in capital markets, where institutions like Harvard University's endowment have recently invested $443 million in BlackRock's Bitcoin ETF, signaling growing institutional confidence in crypto assets. Meanwhile, Japanese exchange Coincheck's pending Nasdaq listing underscores the sector's maturation.

AIxCrypto's strategic pivot reflects a broader industry shift toward Web3 integration, with companies like Alibaba exploring blockchain-based cross-border payments. The firm's governance restructuring, including an updated 2025 Equity Incentive Plan, aims to align talent retention with long-term shareholder value.

Qualigen's transition from oncology and immunology therapies to a crypto-native platform highlights the volatility of biotech markets and the allure of decentralized technologies. The company's forward-looking statements, however, carry risks, including Nasdaq compliance challenges and potential delisting if financial metrics falter.

As the November 20 ceremony approaches, investors will scrutinize AIxCrypto's ability to execute its ambitious roadmap. The event will also introduce a new board structure and chairperson, signaling a pivotal phase for the firm's future.